SCHEMBL202950

SCHEMBL202950

ClCCc1nc2cnc3ccccc3c2n1OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HPGD P15428 2/20 0.39
PDE5A O76074 1/20 0.38
CYP1A2 P05177 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2D6 P10635 2/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
CYP3A4 P08684 1/20 0.36
TLR8 Q9NR97 4/20 0.36
TLR7 Q9NYK1 3/20 0.36
PDE10A Q9Y233 1/20 0.35
ELANE P08246 1/20 0.34
ALDH1A1 P00352 2/20 0.34
TSHR P16473 2/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2708237 0.88 TLR7 (0.44) KMT2AMEN1HPGDPDE5ACYP1A2
SCHEMBL2682348 0.85 TLR7 (0.42) KMT2AMEN1NPSR1HPGDPDE5A
SCHEMBL4130423 0.82 TLR7 (0.43) KMT2AMEN1NPSR1HPGDPDE5A
SCHEMBL2708212 0.79 KMT2A (0.52) KMT2AMEN1NPSR1HPGDPDE5A
SCHEMBL22300852 0.76 TLR7 (0.42) TLR7PDE4APDE4BPDE4CPDE4D
SCHEMBL2709438 0.75 KDM4E (0.40) KMT2AMEN1HPGDCYP1A2CYP2C9
SCHEMBL29882920 0.74 ADORA3 (0.41) TLR8TLR7PDE4APDE4BPDE4C
SCHEMBL22336413 0.74 ADORA3 (0.41) TLR8TLR7PDE4APDE4BPDE4C
SCHEMBL311098 0.73 PDE5A (0.40) KMT2AMEN1NPSR1HPGDPDE5A
SCHEMBL13968055 0.73 TLR7 (0.55) TLR8TLR7PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed
WO-2007106852-A2 SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 KMT2A 3293/4885MEN1 4112/4885NPSR1 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.